Journal of Pharmacy and Pharmaceutical Sciences最新文献

筛选
英文 中文
Development and validation of an LC-MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies. 开发和验证用于鲁索利替尼定量的 LC-MS/MS 方法:推进血液恶性肿瘤的个性化治疗。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-06-28 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.12905
Na Li, Huiying Zhang, Haochen Bai, Kaizhi Lu
{"title":"Development and validation of an LC-MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies.","authors":"Na Li, Huiying Zhang, Haochen Bai, Kaizhi Lu","doi":"10.3389/jpps.2024.12905","DOIUrl":"10.3389/jpps.2024.12905","url":null,"abstract":"<p><strong>Background: </strong>Hematologic malignancies such as leukemia and lymphoma present treatment challenges due to their genetic and molecular heterogeneity. Ruxolitinib, a Janus kinase (JAK) inhibitor, has demonstrated efficacy in managing these cancers. However, optimal therapeutic outcomes are contingent upon maintaining drug levels within a therapeutic window, highlighting the necessity for precise drug monitoring.</p><p><strong>Methods: </strong>We developed a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify ruxolitinib in human plasma, improving upon traditional methods in specificity, sensitivity, and efficiency. The process involved the use of advanced chromatographic techniques and robust mass spectrometric conditions to ensure high accuracy and minimal matrix effects. The study was conducted using samples from 20 patients undergoing treatment, with calibration standards ranging from 10 to 2000 ng/mL.</p><p><strong>Results: </strong>The method displayed linearity (<i>R</i> <sup>2</sup> > 0.99) across the studied range and proved highly selective with no significant interference observed. The method's precision and accuracy met FDA guidelines, with recovery rates consistently exceeding 85%. Clinical application demonstrated significant variability in ruxolitinib plasma levels among patients, reinforcing the need for individualized dosing schedules.</p><p><strong>Conclusion: </strong>The validated LC-MS/MS method offers a reliable and efficient tool for the therapeutic drug monitoring of ruxolitinib, facilitating personalized treatment approaches in hematologic malignancies. This approach promises to enhance patient outcomes by optimizing dosing to reduce toxicity and improve efficacy.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"12905"},"PeriodicalIF":2.9,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic flux in macrophages in obesity and type-2 diabetes. 肥胖和 2 型糖尿病患者巨噬细胞中的代谢通量。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-06-26 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13210
Angela Wong, Qiuyu Sun, Ismail Ibrahim Latif, Qutuba G Karwi
{"title":"Metabolic flux in macrophages in obesity and type-2 diabetes.","authors":"Angela Wong, Qiuyu Sun, Ismail Ibrahim Latif, Qutuba G Karwi","doi":"10.3389/jpps.2024.13210","DOIUrl":"10.3389/jpps.2024.13210","url":null,"abstract":"<p><p>Recent literature extensively investigates the crucial role of energy metabolism in determining the inflammatory response and polarization status of macrophages. This rapidly expanding area of research highlights the importance of understanding the link between energy metabolism and macrophage function. The metabolic pathways in macrophages are intricate and interdependent, and they can affect the polarization of macrophages. Previous studies suggested that glucose flux through cytosolic glycolysis is necessary to trigger pro-inflammatory phenotypes of macrophages, and fatty acid oxidation is crucial to support anti-inflammatory responses. However, recent studies demonstrated that this understanding is oversimplified and that the metabolic control of macrophage polarization is highly complex and not fully understood yet. How the metabolic flux through different metabolic pathways (glycolysis, glucose oxidation, fatty acid oxidation, ketone oxidation, and amino acid oxidation) is altered by obesity- and type 2 diabetes (T2D)-associated insulin resistance is also not fully defined. This mini-review focuses on the impact of insulin resistance in obesity and T2D on the metabolic flux through the main metabolic pathways in macrophages, which might be linked to changes in their inflammatory responses. We closely evaluated the experimental studies and methodologies used in the published research and highlighted priority research areas for future investigations.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13210"},"PeriodicalIF":2.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetics, pharmacotherapy, and dietary interventions in childhood obesity. 儿童肥胖症的遗传学、药物疗法和饮食干预。
IF 2.7 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.12861
Joe Eun Son
{"title":"Genetics, pharmacotherapy, and dietary interventions in childhood obesity.","authors":"Joe Eun Son","doi":"10.3389/jpps.2024.12861","DOIUrl":"10.3389/jpps.2024.12861","url":null,"abstract":"<p><p>Childhood obesity has emerged as a major global health issue, contributing to the increased prevalence of chronic conditions and adversely affecting the quality of life and future prospects of affected individuals, thereby presenting a substantial societal challenge. This complex condition, influenced by the interplay of genetic predispositions and environmental factors, is characterized by excessive energy intake due to uncontrolled appetite regulation and a Westernized diet. Managing obesity in childhood requires specific considerations compared with adulthood, given the vulnerability of the critical juvenile-adolescent period to toxicity and developmental defects. Consequently, common treatment options for adult obesity may not directly apply to younger populations. Therefore, research on childhood obesity has focused on genetic defects in regulating energy intake, alongside pharmacotherapy and dietary interventions as management approaches, with an emphasis on safety concerns. This review aims to summarize canonical knowledge and recent findings on genetic factors contributing to childhood obesity. Additionally, it assesses the efficacy and safety of existing pharmacotherapies and dietary interventions and suggests future research directions. By providing a comprehensive understanding of the complex dynamics of childhood obesity, this review aims to offer insights into more targeted and effective strategies for addressing this condition, including personalized healthcare solutions.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"12861"},"PeriodicalIF":2.7,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. 真实世界数据:关于将其纳入卫生技术评估流程的障碍、挑战和机遇的综合文献综述。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-02-28 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.12302
Konstantinos Zisis, Elpida Pavi, Mary Geitona, Kostas Athanasakis
{"title":"Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.","authors":"Konstantinos Zisis, Elpida Pavi, Mary Geitona, Kostas Athanasakis","doi":"10.3389/jpps.2024.12302","DOIUrl":"10.3389/jpps.2024.12302","url":null,"abstract":"<p><p><b>Objective:</b> This review aimed to assess the current use and acceptance of real-world data (RWD) and real-world evidence (RWE) in health technology assessment (HTA) process. It additionally aimed to discern stakeholders' viewpoints concerning RWD and RWE in HTA and illuminate the obstacles, difficulties, prospects, and consequences associated with the incorporation of RWD and RWE into the realm of HTA. <b>Methods:</b> A comprehensive PRISMA-based systematic review was performed in July 2022 in PubMed/Medline, Scopus, IDEAS-RePEc, International HTA database, and Centre for Reviews and Dissemination with <i>ad hoc</i> supplementary search in Google Scholar and international organization websites. The review included pre-determined inclusion criteria while the selection of eligible studies, the data extraction process and quality assessment were carried out using standardized and transparent methods. <b>Results:</b> Twenty-nine (<i>n</i> = 29) studies were included in the review out of 2,115 studies identified by the search strategy. In various global contexts, disparities in RWD utilization were evident, with randomized controlled trials (RCTs) serving as the primary evidence source. RWD and RWE played pivotal roles, surpassing relative effectiveness assessments (REAs) and significantly influencing decision-making and cost-effectiveness analyses. Identified challenges impeding RWD integration into HTA encompassed limited local data access, complexities in non-randomized trial design, data quality, privacy, and fragmentation. Addressing these is imperative for optimal RWD utilization. Incorporating RWD/RWE in HTA yields multifaceted advantages, enhancing understanding of treatment efficacy, resource utilization, and cost analysis, particularly via patient registries. RWE complements assessments of advanced therapy medicinal products (ATMPs) and rare diseases. Local data utilization strengthens HTA, bridging gaps when RCT data is lacking. RWD aids medical device decision-making, cancer drug reassessment, and indirect treatment comparisons. Challenges include data availability, stakeholder acceptance, expertise, and privacy. However, standardization, training, collaboration, and guidance can surmount these barriers, fostering enhanced RWD utilization in HTA. <b>Conclusion:</b> This study highlights the intricate global landscape of RWD and RWE acceptance in HTA. Recognizing regional nuances, addressing methodological challenges, and promoting collaboration are pivotal, among others, for leveraging RWD and RWE effectively in healthcare decision-making.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"12302"},"PeriodicalIF":2.9,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs. 更正:呼出气体冷凝物分析在药物监测和吸入药物生物等效性研究中的应用。
IF 2.7 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2023-12-18 eCollection Date: 2023-01-01 DOI: 10.3389/jpps.2023.12042
Nastaran Hashemzadeh, Elaheh Rahimpour, Abolghasem Jouyban
{"title":"Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs.","authors":"Nastaran Hashemzadeh, Elaheh Rahimpour, Abolghasem Jouyban","doi":"10.3389/jpps.2023.12042","DOIUrl":"https://doi.org/10.3389/jpps.2023.12042","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.18433/jpps33121.].</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"26 ","pages":"12042"},"PeriodicalIF":2.7,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Traditional Chinese medicine for treating aplastic anemia 治疗再生障碍性贫血的中药
4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2023-11-13 DOI: 10.3389/jpps.2023.11863
Jing Guan, YiHui Zhao, Ting Wang, Rong Fu
{"title":"Traditional Chinese medicine for treating aplastic anemia","authors":"Jing Guan, YiHui Zhao, Ting Wang, Rong Fu","doi":"10.3389/jpps.2023.11863","DOIUrl":"https://doi.org/10.3389/jpps.2023.11863","url":null,"abstract":"Aplastic anemia (AA) is a bone marrow failure disease caused by T cell hyperfunction. Although the overall response rate has been improved by immunosuppressive therapy (IST) plus Eltrombopag, 30% of patients have either no response or relapse. We therefore attempted to find other ways to improve the outcomes of AA patients. Traditional Chinese medicine has the advantages of low cost, reasonable effects, and few side effects. More and more clinical studies have confirmed that traditional Chinese medicine has a beneficial role in treating AA patients. This article reviews the potential mechanism of traditional Chinese medicine or its active ingredients in the treatment of AA. These include improving the bone marrow microenvironment, regulating immunity, and affecting the fate of hematopoietic stem cells. This provides useful information for further treatment of AA with integration of traditional Chinese and Western medicine and the development of new treatment strategies.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"66 50","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches 目前肝纤维化治疗的研究:在重新使用fda批准的药物和其他新兴方法之间
4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2023-11-07 DOI: 10.3389/jpps.2023.11808
Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, Marawan A. Elbaset, Hany M. Fayed
{"title":"Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches","authors":"Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, Marawan A. Elbaset, Hany M. Fayed","doi":"10.3389/jpps.2023.11808","DOIUrl":"https://doi.org/10.3389/jpps.2023.11808","url":null,"abstract":"Long-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposing current FDA-approved drugs targeting etiological molecular factors involved in developing liver fibrosis. In parallel, investigations also focus on experimental small molecules with evidence to hinder or reverse the fibrosis. Natural compounds, immunological, and genetic approaches have shown significant encouraging effects. This review summarizes the efficacy and safety of current under-investigation antifibrosis medications targeting various molecular targets, as well as the properties of antifibrosis medications, mainly in phase II and III clinical trials.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"37 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135476617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Level of service satisfaction of health BPJS patients with drug services at pharmacy X Sibolga City Sibolga市X药房健康BPJS患者用药服务满意度
4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2023-11-07 DOI: 10.36490/journal-jps.com.v6i4.292
Salmah Handayani Lubis, Fenny Hasanah, Eva Sartika Dasopang, Lathifur Rasyidah Tanjung
{"title":"Level of service satisfaction of health BPJS patients with drug services at pharmacy X Sibolga City","authors":"Salmah Handayani Lubis, Fenny Hasanah, Eva Sartika Dasopang, Lathifur Rasyidah Tanjung","doi":"10.36490/journal-jps.com.v6i4.292","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.292","url":null,"abstract":"Health-related issues are one of the most pressing needs of society. Indonesia has government-run health insurance that is directly under its control. When patients obtain services that are considered appropriate or above expectations, patient satisfaction is achieved. This research uses a survey research approach and is descriptive. Surveys distributed to respondents were used to collect data. Eighty respondents who met the inclusion requirements were sampled. The data used is primary data, information obtained directly from respondents, with data collection methods such as providing questionnaires, which are filled in by the respondents themselves and sent back to the researcher. The findings of the study, which were based on SPSS patient characteristics analysis, showed that females accounted for the most significant percentage of respondents (43), followed by the 46-55 years age group (32.5%) and housewives (27.5%), (n=26; 32.5%) had the highest hypertension diagnosis on SPSS analysis, while (n=18; 69%) had the highest drug name of amlodipine. The results, according to the Servqual model, showed that the guarantee dimension had the largest average of 98%(Assurance), while the responsiveness dimension had the lowest average of 92% (waiting time).","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"181 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135480592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uji antibakteri gel hand sanitizer ekstrak daun bawang (Allium fistulosum) tehadap bakteri Staphylococcus aureus 春葱提取物洗手凝胶对金黄色葡萄球菌的抗菌试验
4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2023-11-06 DOI: 10.36490/journal-jps.com.v6i4.263
Nurasni Nurasni, Elfia Neswita
{"title":"Uji antibakteri gel hand sanitizer ekstrak daun bawang (Allium fistulosum) tehadap bakteri Staphylococcus aureus","authors":"Nurasni Nurasni, Elfia Neswita","doi":"10.36490/journal-jps.com.v6i4.263","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.263","url":null,"abstract":"Kemampuan penghambatan pertumbuhan bakteri dari gel handsanitizer adalah cukup baik. Daun bawang (Allium fistulosum) memiliki kandungan allicin yang dapat berfungsi sebagai penghambatan pertumbuhan bakteri Staphylococcus aureus. Tujuan dari penelitian ini adalah untuk menguii aktivitas antibakteri Staphylococcus aureus dari gel Hand Sanitizer yang mengandung estrak daun bawang. Prosedur meliputi pembuatan simplisia, karakterisasi dan pembuatan ekstrak melalui maserasi dengan konsentrasi 20%, 30% dan 40%, lalu dikakukan uji antibakteri dengan metode fifusi agar. Hasil uji tersebut didapatkan penghambatan bakteri dengan zona pada konsentrasi 20%, 30% dan 40% secara berturut-turut adalah 3,5 mm; 5,0 mm; dan 5,9 mm dengan kategori sedang. Kesimpulan dari penelitian ini adalah di dapatkan formulasi dengan konsentrasi terbaik adalah formulasi dengan konsentrasi ekstrak daun bawang sebesar dengan zona hambat bakteri Staphylococcus aureus adalah kategori sedang.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"56 16","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135684046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uji Aktivitas Antioksidan Ekstrak Bunga Telang (Clitoria ternatea L.) Dengan Metode DPPH (2,2 DIiphenyl 1-1 Pickrylhydrzyl) 测试泰朗花提取物的抗氧化活性(Clitoria ternatea L)方法DPPH(2,2捆绑式1- pickrylhyzyl)
4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2023-11-02 DOI: 10.36490/journal-jps.com.v6i4.290
Yulia Kusumanti, Eldesi Medisa Ilmawati, Usti Fina Hasanah Hasibuan
{"title":"Uji Aktivitas Antioksidan Ekstrak Bunga Telang (Clitoria ternatea L.) Dengan Metode DPPH (2,2 DIiphenyl 1-1 Pickrylhydrzyl)","authors":"Yulia Kusumanti, Eldesi Medisa Ilmawati, Usti Fina Hasanah Hasibuan","doi":"10.36490/journal-jps.com.v6i4.290","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.290","url":null,"abstract":"Latar Belakang: Saat ini keadaan masyarakat Indonesia secara umum sedang memprihatinkan. Masyarakat ingin memilih menggunakan kendaraan bermotor untuk bepergian dibandingkan berjalan kaki atau bersepeda. Semua ini menyebabkan peningkatan jumlah radikal bebas dalam tubuh. Antioksidan diperlukan untuk mengatasi bahaya radikal bebas. Indonesia sangat kaya akan sumber daya alam termasuk berbagai tumbuhan, salah satunya adalah bunga telangi (clitoriaternatea l.) yang diduga memiliki aktivitasantioksidan.Tujuan Penelitian:untuk mengetahui aktivitas antioksidan pada bunga telang (Clitoria ternatea L.) dengan metode dpph (dua,dua-Diphenyl 1-1 Picrylhydrazyl).Metode:Ujiaktvitas antioksidan dapat dilakukan dengan memakai beberapa macam metode yaitu dpph, abts. Hasil : Penggolongan senyawa metabolit sekunder yang terdapat pada bunga telang (Clitoria ternatea L.) diantaranya adalah alkaloid, flavonoid, quinon, saponin, tanin, dan steroid dengan teknik yang digunakan dengan uji DPPH. Hasil sampel uji ekstrak bunga telang (Clitoria ternatea L.) mempunyai IC50 sebesar 356,65 ppm dan digolongkan sangat lemah. Penilaian nilai IC50 pada ekstak etanol bunga telang (Clitoria ternatea L.) dengan pelarut metanol memiliki nilai 95. Kesimpulan : Penilaian aktivitas antioksidan dapat dinilai dari IC50. Penilaian IC50 pada bunga telang (Clitoria ternatea L.) yang telah didapatkan hasil yang berbeda-beda, yaitu IC50 lemah dan kuat.Hal ini dapat dipengaruhi oleh panjang gelombang maksimum yang digunakan, serta suhu penyimpanan ekstrak suatu tanaman. Disamping itu, dibutuhkan pelarut yang baik, yaitu metanol, dalam pengukuran IC50 pada bunga telang (Clitoria ternatea L.) dengan menggunakan DPPH.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"66 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135975483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信